Immuneering (IMRX) Capital Expenditures (2020 - 2026)
Immuneering (IMRX) reported Capital Expenditures of $15,158 for Q3 2026, up 108.9% from $7,255 a year earlier but down 44.6% from the prior quarter.
Powered by 
Analysis
Immuneering (IMRX) Capital Expenditures (2020 - 2026) Analysis & Trends
Over the twelve months ended Sep 30, 2026, Immuneering's Capital Expenditures came in at $246,365, up 790.3% year-over-year; for FY2025, it was $142,226, up 67.6% from FY2024.
- Capital Expenditures has a five-year compound annual growth rate of 21.6% (FY2020 to FY2025).
- By year, Capital Expenditures came in at $84,875 in FY2024 (-75.2%), $342,746 in FY2023 (-53.8%), $742,483 in FY2022 and $60,786 in FY2021 (+13.8%).
- Five-year quarterly Capital Expenditures spans a low of $2,116 in Q2 2025 and a high of $393,134 in Q3 2022.
- Year over year, Capital Expenditures gained in three of the last six quarters, with growth averaging 112.7%.
- The high point for year-over-year Capital Expenditures in five years was Q1 2026 (growth of 793.6%); the low point was Q4 2024 (a decline of 94.5%).
- Per Business Quant data, the three quarters before Q3 2026 came in at $27,367 (Q2 2026), $79,930 (Q1 2026) and $123,910 (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,264.65 Bn | 1,238.27 Bn | 20.46 Bn | 3.18 Bn |
| 2 | Johnson & Johnson | 677.74 Bn | 597.60 Bn | 17.30 Bn | 1.36 Bn |
| 3 | AbbVie | 517.10 Bn | 485.11 Bn | 13.12 Bn | 301.00 Mn |
| 4 | Merck | 362.23 Bn | 325.17 Bn | 13.19 Bn | 1.04 Bn |
| 5 | Novartis Ag | 315.90 Bn | 276.16 Bn | 11.24 Bn | 321.00 Mn |
| 6 | Astrazeneca | 289.40 Bn | 266.24 Bn | 12.86 Bn | - |
| 7 | Amgen | 249.90 Bn | 201.56 Bn | 7.58 Bn | 587.00 Mn |
| 8 | Gilead Sciences | 209.15 Bn | 184.26 Bn | 6.73 Bn | 237.00 Mn |
| 9 | Pfizer | 165.88 Bn | 113.23 Bn | 12.56 Bn | 573.00 Mn |
| 10 | Immuneering | 246.36 Mn | -378.47 Mn | - | 15,158.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 15,158.00 |
| Jun 30, 2026 | 27,367.00 |
| Mar 31, 2026 | 79,930.00 |
| Dec 31, 2025 | 123,910.00 |
| Sep 30, 2025 | 7,255.00 |
| Jun 30, 2025 | 2,116.00 |
| Mar 31, 2025 | 8,945.00 |
| Dec 31, 2024 | 9,356.00 |
| Sep 30, 2024 | 5,268.00 |
| Jun 30, 2024 | 32,773.00 |
| Mar 31, 2024 | 37,478.00 |
| Dec 31, 2023 | 170,918.00 |
| Sep 30, 2023 | 57,149.00 |
| Jun 30, 2023 | 86,686.00 |
| Mar 31, 2023 | 27,993.00 |
| Dec 31, 2022 | 69,302.00 |
| Sep 30, 2022 | 393,134.00 |
| Jun 30, 2022 | 164,997.00 |
| Mar 31, 2022 | 115,050.00 |
| Dec 31, 2021 | 13,052.00 |
API Access
Immuneering Capital Expenditures API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=capital-expenditures&ticker=IMRX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "capital-expenditures", "ticker": "IMRX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=capital-expenditures&ticker=IMRX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();